The modern features of optimal therapy of salpingoforite
Keywords:salpingoophoritis, dysbiosis, miramistin, Tamistol, synbiotics, Bifiten
The aim of the prospective study was to investigate the clinical efficacy of Tamistol and Bifiten in the complex treatment of salpingoophoritis.
Patients and methods. The study involved 152 patients of reproductive age with salpingoophoritis. All women were divided into 3 groups: I – 48 patients received traditional therapy; II – 54 patients who received complex anti-inflammatory treatment with vaginal application of a combined drug containing neomycin sulfate 35,000 IU, polymyxin B sulfate 35,000 IU and nystatin 100,000 IU; III – 50 women, each of whom in addition to traditional therapy received Tamistol and the synbiotic Bifiten. The comparative assessment of the effectiveness of treatment was conducted on the basis of regression of women’s complaints and the results of bacteriological research in dynamics.
Results. The local application of suppositories Tamistol or combined drug with neomycin sulfate, polymyxin B sulfate and nystatin had a pronounced clinical effect in the treatment of salpingooophoritis. However, the use of suppositories of Tamistol and Bifiten capsules were more effective than the use of combined drug to reduce the incidence of dysbiosis (RR 2.01, 95% CI 1.14–3.53, p = 0.02 and RR 4.63, 95% CI 1.43–15.04, p = 0.01), for a higher number of lactobacilli (RR 1.99, 95% CI 1.17–3.40, p = 0.011 and RR 5.45 95% CI 1,71–17,41, p = 0,004) on the 14th and 30th day of the study.
Conclusion. Use of suppositories Tamistol and capsules Bifiten was clinically highly effective in the complex therapy of salpingoophoritis. The combination of suppositories Tamistol and Bifiten capsules per os requires further investigation.
- Antonenko, I.V. “Сurrent pathogenetic aspects of the treatment of inflammatory diseases of internal female reproductive organs.” Reproductive Endocrinology 4.30 (2016): 70–4.
- Gorpynchenko, I.I., Gurzhenko, I.M. “The usage of medicine Miramistin during complex treatment of patients with chronic urethritis and urethroprostatitis.” Men’s Health 3 (2013): 78–81.
- Kosei, N.V. “Modern principles of pelvic inflammatory diseases treatment.” In: Reproductive Endocrinology. Almanac of reproductive health. Kyiv (2013): 182–92.
- Markin, L.B., Shakhova O.V. “New approaches to antimicrobial and anti-inflammatory therapy of urogenital infections.” Clinical Pharmacy, Pharmacotherapy and Medical Standardization 3–4 (2015): 110–3.
- Pyrohova, V.I., Shurpyak, S.A. “The prospect of using synbiotics Bifiten in clinical practice obstetricians and gynecologists.” Women’s Health 10.106 (2015): 65–8.
- Tsmur, O.V., Levchuk, O.B., Liashyna, K.V., Boyko, N.V. “Results of using the domestic synbiotic Bifiten for treatment of bacterial vaginosis of pregnant women.” Women’s Health 6.12 (2016): 70–5.
- Falagas, M.E., Betsi, G.I., Athanasiou, S. “Probiotics for the treatment of women with bacterial vaginosis.” Clin Microbiol Infect 13 (2007): 657–64.
- Shenderov, B.A. “Probiotics, prebiotics and synbiotics. General and selected fields of problem.” Food ingredients. Raw materials and additives 2 (2005): 23–6.
How to Cite
Copyright (c) 2017 О. В. Булавенко, Д. Г. Коньков, О. М. Гончаренко
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.